Home > Neurology > EAN 2022 > Letter from the Editor

Letter from the Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany
EAN 2022

Dear colleagues,

After 2 years, this year’s EAN meeting welcomed participants again in person in Vienna and online, creating a true hybrid meeting. More than 8,000 neurologists participated in  this event that highlighted research from all areas of neurology. Recent advances in disease classification, diagnosis, pathobiology and new treatments were presented.

It was an exciting return to meet face-to-face again, learning, sharing and networking together in-person.

With this report we bring you some of the very best content of the meeting, including updated guidelines, new potential biomarkers, real-world data, and not unexpected news on COVID19.

There were lively discussions during live Q&A sessions and in the chatrooms. The main meeting was preceded by a range of excellent teaching courses providing high level postgraduate educational sessions.

As always, our summaries are written independently and are peer-reviewed for balance. We hope you find this edition informative, engaging, and balanced and thank you again for your readership.

Prof Hans-Peter Hartung



Prof. Hartung is currently Professor of Neurology at Heinrich-Heine-University Düsseldorf, Honorary Professor at Brain and Mind Center, University of Sydney, Visiting Professor at Medical University Vienna and Palacky University Olomouc. He was chairman of the Department of Neurology, Heinrich-Heine-University Düsseldorf from 2001-2020, director of the Center for Neurology and Neuropsychiatry from 2012-2020 and director of the Department of Conservative Medicine from 2012-2019.
Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies, development of new immunological, neuroprotective and neural repair promoting strategies. He has (co-)authored more than 950 articles in peer-reviewed journals and 100 book chapters. He has been involved as member of the Steering Committee in numerous international multicentre therapeutic phase 2 and 3 trials in multiple sclerosis, Guillain-Barré Syndrome and CIDP.
He was President of ECTRIMS and has served/ serves amongst others on the executive boards of the European Charcot Foundation, the European Neurological Society, and the International Multiple Sclerosis Cognition Society (IMSCOGS). He is/was also member of the Editorial Board of a number of international journals. Prof. Hartung is a Fellow of the AAN and EAN, and has been chair/ member of the management group of the EAN scientific panels on general neurology and multiple sclerosis. He is Corresponding and Honorary Fellow of several international societies.


Conflict of Interest Statement:

Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, Teva, TG Therapeutics, and Viela Bio, with approval by the Rector of Heinrich-Heine University.

Posted on